A. Rasheed

发表

Proteomic profiling of patient‐derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development

K. Hoadley, S. Keir, D. Bigner, 2015, Journal of neurochemistry.

Expression of O6-methylguanine-DNA methyltransferase in malignant human glioma cell lines.

L. Ostrowski, S. Bigner, T. Brent, 1991, Carcinogenesis.

MRP3: a molecular target for human glioblastoma multiforme immunotherapy.

R. McLendon, G. Riggins, D. Bigner, 2010, BMC Cancer.

Expression of O6-methylguanine-DNA methyltransferase in six human medulloblastoma cell lines.

S. Batra, L. Ostrowski, S. Bigner, 1992, Cancer research.

Expression of 06-Methylguanine-DNA Methyltransferase in Six Human Medulloblastoma Cell Lines 1

D. Bigner, S. Batra, L. Ostrowski, 2006 .

Mismatch Repair Deficiency Does Not Mediate Clinical Resistance to Temozolomide in Malignant Glioma

R. McLendon, A. Friedman, D. Bigner, 2008, Clinical Cancer Research.

Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress.

R. McLendon, Hai Yan, D. Bigner, 2009, Cancer research.

Exomic Sequencing of Four Rare Central Nervous System Tumor Types

Gary L. Gallia, Yuchen Jiao, Yuxuan Wang, 2013, Oncotarget.

Molecular markers of prognosis in astrocytic tumors

R. McLendon, D. Bigner, S. Bigner, 2002, Cancer.

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

R. McLendon, A. Friedman, K. Kinzler, 2012, Oncotarget.

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas

Darell D. Bigner, Jie He, Roger E. McLendon, 2014, Oncotarget.

Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress.

R. McLendon, Hai Yan, D. Bigner, 2009, Cancer research.

Exomic Sequencing of Four Rare Central Nervous System Tumor Types

Zev A. Binder, R. McLendon, L. Wood, 2013, Oncotarget.